Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Cytology

Cytopathology in focus: What’s new in ’25 head and neck SCC guideline?

August 2025—Human papillomavirus testing has become the standard of care in head and neck squamous cell carcinoma (HNSCC) because of the unique clinical features, staging, and treatment options for HPV-associated HNSCC. HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) exhibits a favorable prognosis and improved response to chemoradiation compared with conventional HNSCC and non-HPV-associated forms, and reporting the HPV status is frequently part of clinical trial enrollments. Many patients with OPSCC present with enlarged level II or III cervical lymph nodes and, as a result, cervical lymph node fine-needle aspiration is often the first, and sometimes only, tissue obtained for diagnostic testing. With a growing menu of options available to test for HPV status, including polymerase chain reaction, DNA in situ hybridization, mRNA ISH, liquid-based HPV assays, and p16 immunohistochemistry, it is not always clear when and which HPV test to use, especially when the diagnosis is made on a cytology specimen.

Granulomas on FNA: recognizing and ruling out malignancy

May 2025—Granulomas are organized clusters of immune cells that form as part of the body’s chronic inflammatory response, typically triggered by persistent antigens, chronic infections, or immune dysregulation. They develop when macrophages are activated, transforming into epithelioid histiocytes and multinucleated giant cells (MGC) in response to ongoing immune stimulation. Granulomas are usually surrounded by T lymphocytes, fibroblasts, and extracellular matrix components. While granulomas are most often associated with infections or autoimmune conditions like sarcoidosis, they can arise in a variety of other processes, including malignancy.

Claudin 18.2: a new therapeutic target: What are the implications for cytopathologists?

May 2025—Claudin 18.2 (CLDN18.2), an isoform of claudin-18, is a transmembrane tight junction protein essential for maintaining barrier function and cell polarity in normal gastric and pancreatic epithelium. In malignant epithelial cells, the loss of polarity exposes the CLDN18.2 epitope, leading to its increased expression in gastric and pancreatic adenocarcinomas. CLDN18.2 has drawn attention as a therapeutic target, particularly with the development of the monoclonal IgG antibody zolbetuximab (Vyloy, Astellas Pharma). Zolbetuximab exerts its antitumor effects via both antibody-dependent and complement-mediated cytotoxicity and has demonstrated significantly improved progression-free and overall survival when combined with standard chemotherapy in two pivotal phase three clinical trials (SPOTLIGHT and GLOW). These data validated CLDN18.2 as a promising target in advanced, HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma.

The shift from cotesting to primary HPV screening

February 2025—Eric Huang, MD, PhD, is the first to admit that when it came time to switch to primary HPV testing, his laboratory at the University of Washington faced fewer obstacles than most. Dr. Huang joined the university in 2018 as director of the cytopathology laboratory.

Transition time for primary HPV screening

January 2025—In the 2024 edition of the CAP accreditation checklists, released on Dec. 26, laboratories can expect to see small but significant changes to the all common, cytopathology, and microbiology checklists. These revisions and additions are meant to ensure test quality as more laboratories begin to offer primary HPV screening and p16/Ki-67 dual stain triage.

Pearls and pitfalls in renal mass biopsy

January 2025—Renal mass biopsy has become an indispensable pre-management diagnostic tool, especially as incidental renal masses are increasingly detected with modern imaging techniques. It offers the patient the opportunity to get a definitive diagnosis without necessitating nephrectomy, especially helpful for patients with advanced disease or those who are poor surgical candidates. This is crucial, as certain renal cell carcinoma (RCC) subtypes have significantly different prognostic outcomes and therapeutic implications, making it essential to subtype RCCs in addition to distinguishing between benign and malignant lesions. For instance, systemic treatment strategies diverge markedly between clear cell RCC and non-clear cell RCC subtypes, underscoring our role in guiding personalized therapy choices. This article synthesizes key findings and diagnostic challenges most encountered on renal mass biopsy, with a focus on clear cell RCC, clear cell papillary renal cell tumor, TFE3-rearranged RCC, papillary RCC, oncocytoma, and chromophobe RCC.

A win for all: clinical affiliation with cytology training programs

January 2025—It is well documented that the cytologist/cytotechnologist workforce is diminishing and the number of training programs has declined. According to the Centers for Medicare and Medicaid Services, CT participation in gynecologic proficiency testing has decreased by 27 percent since 2005. New board certifications of CTs or specialists in CT(SCT) decreased by about 56 percent over the same period. CT(ASCP) and all SCT(ASCP) certifications are now recognized by the CMS and the Centers for Disease Control and Prevention per 42 CFR §493.1483.

Beyond the microscope: expanding the role of cytopathologists

January 2025—The traditional image of a pathologist is often that of a scientist working in a laboratory, handling chemical solutions, or peering through a microscope. Over the past decade, pathologists, including those specializing in cytopathology, have increasingly moved beyond those confines, taking on more prominent roles in patient-facing care. This article explores the various ways cytopathologists are expanding their roles, engaging directly with patients and physicians and positioning themselves at the forefront of the management team.

Inside new edition of gyn cytopathology guide

November 2024—New this month from CAP Publications is the CAP Practical Guide to Gynecologic Cytopathology—Morphology, Management, and Molecular Methods, second edition. Its 15 chapters cover squamous and glandular epithelial abnormalities, anal cytology, benign changes and mimics of premalignant and malignant epithelial lesions, and much more. In this issue we provide part of the chapter on look-alikes and morphologic spectrums of change.

Self-collected vaginal swabs studied for HPV tests

September 2024—In HPV primary screening, self-collected vaginal samples enable accurate clinical HPV testing, and neither extended ambient dry storage nor exposure to extreme temperatures influence HPV detection, say the authors of a study published in June.

MARKETPLACE

TRENDING